Trasylol Tagged Articles
Follow-up to Canadian BART study confirms Trasylol risks
A report released yesterday underlines the danger of Trasylol (aprotinin), which was used for years to limit bleeding during surgery. Trasylol was taken off the market last year after U.S. tests indicated the drug posed a significantly higher risk of
Pre-emption could give Bayer an escape from Trasylol case
Zero accountability for drug companies? Bloomberg recently ran an article about pharmaceutical companies enjoying their “get out of jail free cards” — revisions to regulations that favor the rights of pharmaceutical companies over consumers who use their drugs. The revised
Zero accountability for drug companies?
Bloomberg recently ran an interesting and comprehensive article about pharmaceutical companies enjoying their “get out of jail free cards” — revisions to regulations that favor the rights of pharmaceutical companies over consumers who use their drugs. The revised regulations, written
FDA warns Bayer about two OTC aspirin products
The Food and Drug Administration sent Bayer Health Care official warnings, stating that the company is marketing and selling two over-the-counter medications that are “illegal,” according to FDA spokeswoman Rita Chappelle. The two aspirin products, Bayer Women’s Low Dose Aspirin
Two suits filed against Bayer in Illinois
Two Illinois residents have filed suit against Bayer, claiming that Trasylol injections led to acute renal failure and other problems in one case and death in the other.
Trasylol Pulled From Worldwide Market
Bayer AG suspended worldwide sales of Trasylol, a clotting drug using during heart surgery to prevent bleeding, on Monday following a request from the U.S. Food and Drug Administration to remove the drug from the American market for safety reasons.
One in fifty Trasylol patients dies
A conclusive study of Bayer AG’s aprotinin injection Trasylol uncovered a grim fact: one out of every 50 Trasylol recipients dies. The study was conducted in Canada and involved monitoring the health of 2,331 high-risk heart patients.
FDA announces withdrawal of remaining Trasylol
The FDA announced today that Bayer Pharmaceuticals Corp. will begin removing all remaining supplies of the drug Trasylol (aprotinin) from warehouses and other medical stock. The decision comes following the preliminary results of a test that showed the drug greatly
Trasylol: just one of Bayer’s woes
An article in this week’s Business Week reveals a dualistic Bayer. On one hand, the pharmaceutical giant is “flush with success,” with projected sales just shy of $50 billion and increased dividends for shareholders. On the other hand, Bayer has
Death by Trasylol: one man’s story
Joseph Randone was a healthy 52-year old family man from Long Island when he underwent heart valve replacement surgery at Stony Brook University Hopsital in New York. The risks were low, according to his surgeon. Joe would likely return home